Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ReNAgade Therapeutics
CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
April 29, 2024
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
April 22, 2024
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
February 27, 2024
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors
December 05, 2023
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference
October 30, 2023
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics Named to the 2023 Endpoints 11
September 21, 2023
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
September 12, 2023
From
ReNAgade Therapeutics
Via
Business Wire
ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine
May 23, 2023
From
ReNAgade Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.